DK0701572T3 - Sammensat syntetisk peptidkonstruktion, der fremkalder neutraliserende antistoffer og cytotoksiske T-lymfocytter mod HIV - Google Patents
Sammensat syntetisk peptidkonstruktion, der fremkalder neutraliserende antistoffer og cytotoksiske T-lymfocytter mod HIVInfo
- Publication number
- DK0701572T3 DK0701572T3 DK94919119T DK94919119T DK0701572T3 DK 0701572 T3 DK0701572 T3 DK 0701572T3 DK 94919119 T DK94919119 T DK 94919119T DK 94919119 T DK94919119 T DK 94919119T DK 0701572 T3 DK0701572 T3 DK 0701572T3
- Authority
- DK
- Denmark
- Prior art keywords
- hiv
- mice
- peptides
- peptide
- sup
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000003472 neutralizing effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
- 241000699670 Mus sp. Species 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 102000054766 genetic haplotypes Human genes 0.000 abstract 2
- 101710121417 Envelope glycoprotein Proteins 0.000 abstract 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 241000282579 Pan Species 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 230000009696 proliferative response Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 210000004989 spleen cell Anatomy 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/060,988 US6294322B1 (en) | 1988-01-26 | 1993-05-14 | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| PCT/US1994/005142 WO1994026785A1 (fr) | 1993-05-14 | 1994-05-13 | Produits genetiques de peptides synthetiques composites declenchant des anticorps et des lymphocytes t cytotoxiques de neutralisation contre vih |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0701572T3 true DK0701572T3 (da) | 2000-03-13 |
Family
ID=22032969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94919119T DK0701572T3 (da) | 1993-05-14 | 1994-05-13 | Sammensat syntetisk peptidkonstruktion, der fremkalder neutraliserende antistoffer og cytotoksiske T-lymfocytter mod HIV |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US6294322B1 (fr) |
| EP (1) | EP0701572B1 (fr) |
| JP (2) | JP3802049B2 (fr) |
| AT (1) | ATE183200T1 (fr) |
| AU (1) | AU688333B2 (fr) |
| CA (1) | CA2162880C (fr) |
| DE (1) | DE69420034T2 (fr) |
| DK (1) | DK0701572T3 (fr) |
| ES (1) | ES2138086T3 (fr) |
| GR (1) | GR3031790T3 (fr) |
| WO (1) | WO1994026785A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294322B1 (en) * | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| NZ290089A (en) * | 1994-07-27 | 1999-05-28 | Queensland Inst Med Res | Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines |
| WO1997041440A1 (fr) * | 1996-04-26 | 1997-11-06 | Rijksuniversiteit Te Leiden | Procedes de selection et de production d'epitopes peptidiques de lymphocytes t et vaccins contenant lesdits epitopes selectionnes |
| US6749856B1 (en) * | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
| CA2303410A1 (fr) * | 1997-09-11 | 1999-03-18 | The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services | Reponses propres aux muqueuses de cellules t cytotoxiques |
| ES2244214T3 (es) * | 1998-09-15 | 2005-12-01 | Syngenta Participations Ag | Piridincetonas utiles como herbicidas. |
| AU781469B2 (en) | 1999-05-13 | 2005-05-26 | Wyeth Holdings Corporation | Adjuvant combination formulations |
| FR2799465B1 (fr) * | 1999-10-12 | 2004-02-13 | Centre Nat Rech Scient | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire |
| IL150961A0 (en) | 2000-02-04 | 2003-02-12 | Univ Duke | Human immunodeficiency virus vaccine |
| AU2001254561A1 (en) * | 2000-04-27 | 2001-11-12 | Aventis Pasteur Limited | Immunizing against hiv infection |
| WO2002055100A2 (fr) | 2000-10-20 | 2002-07-18 | Genetics Institute, Llc | Procédé et composition pour renforcer une réponse immunitaire |
| KR100863368B1 (ko) * | 2000-11-10 | 2008-10-13 | 와이어쓰 홀딩스 코포레이션 | 조합 보조 제제 |
| US20030162720A1 (en) * | 2001-10-29 | 2003-08-28 | Nicolette Charles A. | Therapeutic anti-HIV (IV9) compounds |
| US20030165517A1 (en) * | 2001-10-29 | 2003-09-04 | Nicolette Charles A. | Therapeutic anti-HIV (vpr) compounds |
| WO2005005465A2 (fr) * | 2003-07-08 | 2005-01-20 | Board Of Regents, University Of Texas System | Procedes et compositions permettant d'ameliorer des reactions immunitaires par l'intermediaire d'antigenes de rappel |
| WO2005111065A2 (fr) * | 2004-04-30 | 2005-11-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Activation d'un epitope du vih cd4 humain |
| US20080038284A1 (en) * | 2004-11-08 | 2008-02-14 | Haynes Barton F | Human Immunodeficiency Virus Vaccine |
| WO2007133573A1 (fr) * | 2006-05-09 | 2007-11-22 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compositions immunogènes anti-vih-1 |
| CA2793959C (fr) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Glycoproteines du cmv et vecteurs recombines |
| EP2691530B1 (fr) | 2011-06-10 | 2018-03-07 | Oregon Health & Science University | Glycoprotéines de cmv et vecteurs recombinants cmv |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| EP2620446A1 (fr) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogènes pour la vaccination contre le VIH |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (fr) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Trimères de glycoprotéines d'enveloppe du vih -1 soluble |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (fr) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
| EP4058058A1 (fr) | 2019-11-14 | 2022-09-21 | Aelix Therapeutics S.L. | Régimes posologiques pour vaccins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294322B1 (en) * | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| US4817966A (en) * | 1988-02-03 | 1989-04-04 | Garlock Inc. | Rotary shaft bearing isolator seal |
| EP0362909A3 (fr) | 1988-08-26 | 1990-11-14 | Akzo N.V. | Polypeptides synthétiques immuno-actifs avec des anticorps VIH |
| EP0448095A1 (fr) | 1990-03-21 | 1991-09-25 | Wolf, Hans Joachim, Prof. Dr. | Sous-région de la protéine ENV rétrovirale, séquences d'ADN codant pour celle-ci et compositions pour le diagnostic, la prévention ou la thérapie des infections rétrovirales |
| AU665023B2 (en) | 1991-08-29 | 1995-12-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Multideterminant peptide antigens that stimulate helper T lymphocyte response to HIV in a range of human subjects |
-
1993
- 1993-05-14 US US08/060,988 patent/US6294322B1/en not_active Expired - Lifetime
-
1994
- 1994-05-13 WO PCT/US1994/005142 patent/WO1994026785A1/fr active IP Right Grant
- 1994-05-13 AT AT94919119T patent/ATE183200T1/de active
- 1994-05-13 ES ES94919119T patent/ES2138086T3/es not_active Expired - Lifetime
- 1994-05-13 CA CA002162880A patent/CA2162880C/fr not_active Expired - Fee Related
- 1994-05-13 DE DE69420034T patent/DE69420034T2/de not_active Expired - Lifetime
- 1994-05-13 JP JP52562494A patent/JP3802049B2/ja not_active Expired - Fee Related
- 1994-05-13 EP EP94919119A patent/EP0701572B1/fr not_active Expired - Lifetime
- 1994-05-13 AU AU70173/94A patent/AU688333B2/en not_active Ceased
- 1994-05-13 DK DK94919119T patent/DK0701572T3/da active
-
1995
- 1995-05-31 US US08/455,625 patent/US5932218A/en not_active Expired - Lifetime
- 1995-05-31 US US08/455,685 patent/US6214347B1/en not_active Expired - Lifetime
-
1999
- 1999-11-10 GR GR990402883T patent/GR3031790T3/el unknown
- 1999-12-06 US US09/455,076 patent/US7094405B1/en not_active Expired - Fee Related
-
2005
- 2005-08-18 JP JP2005238013A patent/JP2006056893A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE69420034D1 (de) | 1999-09-16 |
| US5932218A (en) | 1999-08-03 |
| AU7017394A (en) | 1994-12-12 |
| GR3031790T3 (en) | 2000-02-29 |
| EP0701572A1 (fr) | 1996-03-20 |
| WO1994026785A1 (fr) | 1994-11-24 |
| AU688333B2 (en) | 1998-03-12 |
| CA2162880C (fr) | 2003-02-11 |
| US7094405B1 (en) | 2006-08-22 |
| ES2138086T3 (es) | 2000-01-01 |
| ATE183200T1 (de) | 1999-08-15 |
| US6294322B1 (en) | 2001-09-25 |
| CA2162880A1 (fr) | 1994-11-24 |
| US6214347B1 (en) | 2001-04-10 |
| JPH09500614A (ja) | 1997-01-21 |
| DE69420034T2 (de) | 2000-03-02 |
| EP0701572B1 (fr) | 1999-08-11 |
| JP3802049B2 (ja) | 2006-07-26 |
| JP2006056893A (ja) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0701572T3 (da) | Sammensat syntetisk peptidkonstruktion, der fremkalder neutraliserende antistoffer og cytotoksiske T-lymfocytter mod HIV | |
| Shirai et al. | Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. | |
| US5759769A (en) | Tandem synthetic HIV-1 peptides | |
| Fayolle et al. | Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity | |
| Chanh et al. | Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic response | |
| US5614612A (en) | Purified gp120 compositions retaining natural conformation | |
| EP0436634A1 (fr) | Proteines et peptides du vih utiles pour le diagnostic, la prophylaxie ou la therapie du sida | |
| Lehner et al. | Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. | |
| US5993819A (en) | Synthetic vaccine for protection against human immunodeficiency virus infection | |
| CA2082948A1 (fr) | Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4 | |
| US5817318A (en) | Synthetic peptides for an HIV-1 vaccine | |
| Liao et al. | Increased immunogenicity of HIV envelope subunit complexed with α2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF | |
| CA2077753C (fr) | Composition a base de gp120 purifie conservant sa conformation naturelle | |
| US5820865A (en) | Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides | |
| US5688914A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
| US6080846A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
| EP0762895B1 (fr) | Vaccin de synthese protegeant contre l'infection par le vih | |
| AP502A (en) | Multiple branch peptide constructions for use against HIV. | |
| WO1997014436A9 (fr) | Vaccin de synthese pour la protection contre l'infection par le virus de l'immunodeficience humaine | |
| US5622933A (en) | Multiple branch peptide constructions for use against HIV | |
| Hosmalin et al. | Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1. | |
| ES2322253T3 (es) | Utilizacion de mezclas de lipopeptidos para la fabricacion de vacunas. | |
| DE69008701T2 (de) | Ein b-epitop des hüllglykoproteins eines retrovirus und ein t-epitop eines anderen proteins dieses retrovirus enthaltende zusammensetzung. | |
| Sarobe et al. | Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cells | |
| Benjouad et al. | Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type‐1 envelope glycoprotein |